Loteprednol/tobramycin
| Combination of | |
|---|---|
| Loteprednol | Corticosteroid |
| Tobramycin | Aminoglycoside antibiotic |
| Clinical data | |
| Trade names | Zylet |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Ophthalmic |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Loteprednol/tobramycin, sold under the brand name Zylet, is a fixed-dose combination medication used for the treatment of inflammation of the eye.[1] It is a combination of loteprednol, as the etabonate, a corticosteroid; and tobramycin, an aminoglycoside antibiotic.[1] It is used as drops in the eye.[1]
Loteprednol/tobramycin was approved for medical use in the United States in December 2004.[1]
References[edit]
Further reading[edit]
- O'Gallagher M, Bunce C, Hingorani M, Larkin F, Tuft S, Dahlmann-Noor A (February 2017). "Topical treatments for blepharokeratoconjunctivitis in children". The Cochrane Database of Systematic Reviews. 2017 (2): CD011965. doi:10.1002/14651858.CD011965.pub2. PMC 6464561. PMID 28170093.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |